Blogs
Gephardt, AZ’s Brennan on Innovation: What Is Our Moon Shot?
Category:
FDA
New Drug Pipeline and R&D
AstraZeneca
India
China and Asian Pharma
Pharmaceutical Patents and Intellectual Property
Biotechnology and biopharmaceuticals
Pharmaceutical Industry CEOs
medical research
drug development
orphan drugs
Obama
R&d
Gephardt
Submitted by pharmamanufacturing on Thu, 04/16/2009 - 10:08
I spent yesterday afternoon at the Forum for Medical Innovation in downtown Chicago, hosted by the Council for American Medical Innovation and moderated by former U.S. House of Representatives majority leader Dick Gephardt. The event also featured AstraZeneca CEO David Brennan as a guest speaker. [img_assist|nid=1172|title=David Brennan|desc=|link=none|align=right|width=128|height=86]
Will Chemical Engineers Save Pharma?
Category:
Process Analytical Technologies
The Pharma Industry
New Drug Pipeline and R&D
Pharmaceutical Patents and Intellectual Property
Generic Drugs
Environmental issues and green pharma
Girish Malhotra
drug development
Green Chemistry
Process Validation
Submitted by pharmamanufacturing on Fri, 04/10/2009 - 10:53
From Chemical Engineering Progress, Girish Malhotra presents his prescription for the pharmaceutical industry----QbD, PAT and control all play a key role, and chemical engineers will make it happen. The ultimate goal will be entirely new business models for pharma.
Ranbaxy Relief
Category:
FDA
cGxP's
FDA and Regulatory Issues
Drug Safety
Pharmaceutical Patents and Intellectual Property
Generic Drugs
Ranbaxy
Submitted by pharmamanufacturing on Thu, 10/09/2008 - 12:52
A nice, if brief, Q&A appeared today in India's Business Standard, featuring a conversation with Arun Kumar, CEO of generics maker Strides Arcolab.
Managing Change: What Keeps Pharma CEO’s Awake at Night
Category:
The Pharma Industry
Personalized Medicine
New Drug Pipeline and R&D
Information Technology and Software
Pharmaceutical Patents and Intellectual Property
Pharmaceutical Industry CEOs
Pharmaceutical Industry Goodwill and Philanthropy
Environmental issues and green pharma
Supply Chain Management
management
Drug pricing
drug development
DIA
IBM Life Sciences
patient-centered healthcare
pandemic monitoring and surveillance
Mike Svinte
Submitted by pharmamanufacturing on Wed, 06/25/2008 - 11:11
At a meeting at DIA in Boston yesterday, Mike Svinte, President of Global Life Sciences at IBM provided a sneak peek and insights into a new report probing CEO challenges and concerns and their implications. The report, which is due to be released next month, will distill interviews with more...
Patent Law Reform Vote Expected This Afternoon
Category:
The Pharma Industry
Pharmaceutical Patents and Intellectual Property
Biotechnology and biopharmaceuticals
Pharmaceutical Industry Videos
Submitted by pharmamanufacturing on Wed, 04/18/2007 - 13:58
This afternoon, the Senate will vote on sweeping patent reform measures that are pleasing tech companies but worrying pharma and biopharma (more on this from the Houston Chronicle). Read a report The Department of Justice and FTC released a comprehensive report on the subject this morning, while Bloomberg's Washington correspondent...